Adagrasib Associated With Promising Disease Control Rate in KRAS G12C–Mutant NSCLCJune 9th 2022
Investigators reported an objective response rate of 43% and a disease control rate of 80% among patients with previously treated KRAS G12C–mutated non–small cell lung cancer who received the KRAS G12C inhibitor adagrasib.
Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer TreatmentJune 9th 2021
Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.
Tivozanib Tolerability Shows Potential Advantage for Patients with Advanced RCCMay 20th 2020
Oncology Nursing News sat down with Brian Rini, MD, from the Vanderbilt-Ingram Cancer Center (VICC), to discuss results from the phase III TIVO03 trial, and its potential impact on patients with relapsed or refractory renal cell carcinoma.
FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory MyelomaJanuary 21st 2020
The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma.
FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLCJanuary 16th 2020
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.
Endocrine Toxicities May Be a Unique AE Associated with ImmunotherapyAugust 23rd 2019
Like most other adverse events (AEs), nurses play a vital role in monitoring for and managing endocrine toxicities associated with immunotherapy treatment; however, these may be more unique than others, according to Marianne Davies, DNP, RN, CNS, ACNP-BC, AOCNP.